C1s Inhibitor Compounds With Better Bioavailability and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for pharmaceutically acceptable compounds to inhibit the complement system, particularly the C1 esterase, to treat disorders mediated by its dysfunction, including those arising from the classical, alternative, and lectin pathways, and to address undesired complement-mediated responses to medical treatments or procedures.
Innovation Solution
Development of compounds that inhibit C1s, such as those represented by formulas (I), (II), (III), (IIIa), (IV), (IVa), (V), and (VI), which exhibit improved C1s inhibiting activity, classical pathway hemolysis inhibiting activity, improved bioavailability, and metabolic stability, and can be administered as prodrugs to treat complement-mediated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If structurally related compounds are used to inhibit C1s, then C1s inhibiting activity is achieved, but bioavailability and metabolic stability are insufficient
Solution Approach 1:
The patent modifies the chemical structure of C1s inhibitor compounds by changing parameters such as adding fluorine atoms, modifying ester groups, and adjusting molecular weight to improve bioavailability and metabolic stability while maintaining C1s inhibiting activity. Specific structural modifications include replacing hydroxyl groups with fluorine, changing ester linkages, and optimizing the balance between hydrophilic and hydrophobic regions of the molecule.
2Reliability
If structurally related compounds are used to inhibit C1s, then C1s inhibiting activity is achieved, but metabolic stability is insufficient
Solution Approach 1:
The patent employs parameter changes by introducing metabolically stable groups such as fluorine atoms at positions susceptible to metabolic degradation, replacing labile ester bonds with more stable isosters, and modifying the molecular scaffold to resist enzymatic breakdown. These changes extend the half-life and metabolic stability of the compounds in vivo.
3Reliability
If compounds are designed to inhibit the complement system, then therapeutic benefits are achieved, but structural complexity increases
Solution Approach 1:
The patent segments the inhibitor molecule into distinct functional domains: a core scaffold that binds C1s, substituent groups that modulate pharmacokinetic properties, and prodrug moieties that enhance delivery. This segmentation allows systematic optimization of each domain independently while maintaining overall therapeutic efficacy.
Solution Approach 2:
The patent creates composite molecular structures combining multiple functional elements within a single compound, such as integrating the C1s binding core with metabolically stable substituents and prodrug groups. This composite approach achieves enhanced therapeutic properties without requiring complex mixture formulations.
Data Source
AI summary
This disclosure provides compounds, compositions, and methods to treat medical disorders, such as complement-mediated disorders, including complement C1s-mediated disorders.